Dublin, Jan. 17, 2017 -- Research and Markets has announced the addition of the "Global Anemia Drugs Market (Iron Deficiency, Sickle Cell, CKD, Aplastic Anemia): Analysis By Region, By Country (2016-2021)" report to their offering.
Global Anemia Drugs Market is forecasted to grow at a CAGR of 9.05% during 2016-2021F, on account of rising incidences of anemia globally.
North America region remains the major market followed by Europe in the actual period, while APAC and ROW region will witness strong growth in the forecast period.
According to the report, Global Anemia Drugs Market: Trends, Opportunities and Forecasts (2016-2021), Global Anemia Drugs market is projected to exhibit a CAGR of over -9.05% during 2016-2021.
Scope of the Report
The report provides Segmentation and Pipeline Analysis by Anemia Type
- Iron Deficiency Anemia
- Chronic Kidney Disease related Anemia
- Sickle Cell Anemia
- Aplastic Anemia
Key Topics Covered:
1. Research Methodology
2. Executive Summary
3. Strategic Recommendations
3.1. North America and Europe to Generate High Revenue
3.2. Opportunity in Rare Anemia
3.3. Growing Inclination Towards Hypoxia inducible factor (HIF) Stabilizers
4. Global Anemia Drugs Market: An Overview
4.1. Product Overview
4.2. Global Anemia Drugs Market
4.1.1. By Value (Historic 2011-15)
4.1.2. By Value (Forecast 2016E-2021F)
4.3. Global Iron Deficiency Anemia Drugs Market
4.2.1. By Value (Historic 2011-15)
4.2.2. By Value (Forecast 2016E-2021F)
4.4. Global CKD Anemia Drugs Market
4.4.1. By Value (Historic 2011-15)
4.4.2. By Value (Forecast 2016E-2021F)
4.5. Global Sickle Cell Anemia Drugs Market
4.5.1. By Value (Historic 2011-15)
4.5.2. By Value ( Forecast 2016E-2021F)
4.6. Global Aplastic Anemia Drugs Market
4.6.1. By Value (Historic 2011-15)
4.6.2. By Value ( Forecast 2016E-2021F)
4.7. Anemia Drugs Pipeline Analysis
4.7.1. Sickle Cell Anemia
4.7.2. CKD Anemia
4.7.3. Aplastic Anemia
4.7.4. Iron Deficiency Anemia
4.7.5. Myelodysplastic syndrome Anemia
5. North America Anemia Drugs Market: An Analysis
5.1. North America Anemia Drugs Market
5.1.1.By Value (Historic 2011-15)
5.1.2.By Value (Forecast 2016E-2021F)
5.2. North America Anemia Drugs Market: Country Overview - US, Canada
6. Europe Anemia Drugs Market: An Analysis
6.1. Europe Anemia Drugs Market
6.1.1. By Value (Historic 2011-15)
6.1.2. By Value (Forecast 2016E-2021F)
6.2. Europe Anemia Drugs Market: Country Overview - UK, Germany
7. APAC Anemia Drugs Market: An Analysis
7.1. APAC Anemia Drugs Market
7.1.1.By Value (Historic 2011-15)
7.1.2.By Value (Forecast 2016E-2021F)
7.2. North America Anemia Drugs Market: Country Overview - India
8. Latin America Anemia Drugs Market: An Analysis
8.1. Latin America Anemia Drugs Market
8.1.1.By Value (Historic 2011-15)
8.1.2.By Value (Forecast 2016E-2021F)
8.2. Latin America Anemia Drugs Market: Country Overview - Brazil
9. MEA Anemia Drugs Market: An Analysis
9.1. MEA Anemia Drugs Market
9.1.1.By Value (Historic 2011-15)
9.1.2.By Value (Forecast 2016E-2021F)
9.2. MEA Anemia Drugs Market: Country Overview - South Africa
10. Market Dynamics
10.1. Trends
10.2. Drivers
10.3. Challenges
11. M&A and Licensing Route to the Anemia Drugs Treatment Market
12. SWOT Analysis
13. Porter Five Force Model
14. Company Profiling and Drug Market Potential
- Acceleron Pharma
- Akebia therapeutics
- Bayer AG
- Bluebird bio
- Celgene Corporation
- Eli Lilly
- Fibrogen
- GlaxoSmithKline
- Global Blood Therapeutics (GBT)
- GlycoMimetics
- Mast Therapeutics
- Onconova Therapeutics
- Pieris Pharmaceuticals
- Regen biopharma
For more information about this report visit http://www.researchandmarkets.com/research/65q8mb/global_anemia
About Research and Markets
Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Hematological Drugs


Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
Ford and Geely Explore Strategic Manufacturing Partnership in Europe
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 



